Your browser is no longer supported. Please, upgrade your browser.
Aprea Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.54 Insider Own3.50% Shs Outstand21.19M Perf Week-7.10%
Market Cap91.13M Forward P/E- EPS next Y-1.60 Insider Trans-39.64% Shs Float19.04M Perf Month-21.24%
Income-53.70M PEG- EPS next Q-0.48 Inst Own52.60% Short Float5.74% Perf Quarter-3.46%
Sales- P/S- EPS this Y-89.90% Inst Trans-3.12% Short Ratio0.32 Perf Half Y-37.65%
Book/sh3.26 P/B1.29 EPS next Y8.00% ROA-55.00% Target Price7.25 Perf Year-85.46%
Cash/sh3.57 P/C1.17 EPS next 5Y- ROE-64.00% 52W Range3.88 - 31.45 Perf YTD-14.84%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-86.68% Beta-
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin- 52W Low7.99% ATR0.33
Employees17 Current Ratio7.10 Sales Q/Q- Oper. Margin- RSI (14)37.91 Volatility4.63% 7.42%
OptionableYes Debt/Eq0.00 EPS Q/Q-2.20% Profit Margin- Rel Volume0.14 Prev Close4.25
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.42M Price4.19
Recom2.80 SMA20-12.58% SMA50-12.72% SMA200-57.77% Volume488,402 Change-1.41%
Dec-28-20Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20Initiated Berenberg Buy $37
Sep-29-20Resumed JP Morgan Neutral $25
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
Jul-21-21 08:00AM  
Jun-18-21 08:34AM  
Jun-17-21 09:19AM  
Jun-16-21 09:24AM  
Jun-13-21 12:45PM  
Jun-04-21 01:47AM  
May-21-21 06:00AM  
May-18-21 06:00AM  
May-06-21 04:15PM  
Apr-16-21 09:15AM  
Apr-08-21 11:15AM  
Mar-16-21 04:15PM  
Feb-16-21 08:04AM  
Jan-22-21 12:00PM  
Jan-08-21 08:00AM  
Dec-30-20 11:40AM  
Dec-29-20 07:24PM  
Dec-28-20 04:57PM  
Dec-10-20 10:33PM  
Nov-30-20 08:00AM  
Nov-23-20 10:00AM  
Nov-19-20 08:00AM  
Nov-05-20 04:15PM  
Oct-30-20 04:00AM  
Oct-14-20 08:00AM  
Oct-07-20 08:00AM  
Sep-29-20 08:00AM  
Sep-18-20 08:00AM  
Sep-03-20 08:00AM  
Aug-11-20 04:15PM  
Jul-16-20 07:00AM  
Jul-01-20 10:32AM  
Jun-29-20 07:00AM  
Jun-12-20 04:15PM  
Jun-11-20 10:44PM  
Jun-10-20 09:39AM  
Jun-03-20 08:00AM  
May-27-20 09:21AM  
May-18-20 08:00AM  
May-15-20 07:30AM  
May-11-20 10:57AM  
Apr-27-20 07:00AM  
Apr-06-20 08:00AM  
Apr-02-20 06:11AM  
Mar-26-20 08:00AM  
Feb-13-20 08:00AM  
Jan-30-20 07:30AM  
Jan-09-20 08:00AM  
Jan-03-20 05:56AM  
Dec-17-19 10:08AM  
Dec-12-19 08:30AM  
Dec-09-19 11:00AM  
Dec-07-19 08:35AM  
Nov-29-19 09:24AM  
Nov-14-19 04:15PM  
Nov-11-19 04:40PM  
Nov-06-19 09:15AM  
Oct-11-19 05:01PM  
Oct-08-19 03:59PM  
Oct-07-19 04:15PM  
Oct-03-19 11:09AM  
Oct-02-19 11:03PM  
Sep-30-19 10:21AM  
Sep-23-19 08:55AM  
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLC10% OwnerDec 28Sale5.58500,0002,791,2901,768,718Feb 16 04:11 PM
5AM Ventures IV, L.P.Former 10% holderOct 05Sale25.30175,0004,427,500138,497Oct 07 09:30 PM